Spatiotemporal distribution of Mycobacterium ulcerans and other mycolactone producing mycobacteria in southeastern United States
- PMID: 40525224
- PMCID: PMC12231298
- DOI: 10.1080/22221751.2025.2521853
Spatiotemporal distribution of Mycobacterium ulcerans and other mycolactone producing mycobacteria in southeastern United States
Abstract
Buruli ulcer (BU) is a chronic and debilitating skin disease caused by the environmental pathogen, Mycobacterium ulcerans (MU). The primary virulence determinant is mycolactone, a cytotoxic lipid compound unique to MU and its other mycolactone producing mycobacteria (MPM) ecological variants. Although BU prevalence is highest in West Africa and Australia, little is known about MU and other MPM distribution in non-endemic regions such as the Southeastern United States (US). In this study, environmental samples (water filtrand, plant biofilm, soil, aquatic invertebrates) were collected from nine freshwater sites across Louisiana, Mississippi and Alabama over three sampling periods (August 2020, November 2020, March 2021). Samples were screened for MU and MPM presence and abundance by PCR and genotyped using variable number tandem repeat (VNTR) profiling. All nine sites were positive for MU or other MPM DNA in at least one substrate, except invertebrates. Overall, mean concentrations were 4.3 × 104 genome units (GU)/sample in August 2020, 1.26 GU/sample in November 2020, and 55.5 GU/sample in March 2021. Profiling by VNTR identified four MU (designated A-D) and one M. liflandii genotype(s), among environmental samples, with genotype frequencies varying by site and sampling time. Detection of MU and M. liflandii genotypes in Southeastern US aquatic environments, matching those from BU endemic regions, provides rationale for ongoing surveillance. Our findings broaden the known geographic range of MU and MPMs and offer baseline data to help predict and prevent and predict the possibility of zoonotic transmission in Southeastern US.
Keywords: Alabama; Buruli Ulcer; Louisiana; Mississippi; Mycobacterium liflandii; Mycobacterium ulcerans; Southeastern United States; mycolactone-producing mycobacteria.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Figures





Similar articles
-
Molecular Characterization of Mycolactone Producing Mycobacteria from Aquatic Environments in Buruli Ulcer Non-Endemic Areas in Côte d'Ivoire.Int J Environ Res Public Health. 2017 Feb 11;14(2):178. doi: 10.3390/ijerph14020178. Int J Environ Res Public Health. 2017. PMID: 28208653 Free PMC article.
-
Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).Cochrane Database Syst Rev. 2018 Aug 23;8(8):CD012118. doi: 10.1002/14651858.CD012118.pub2. Cochrane Database Syst Rev. 2018. PMID: 30136733 Free PMC article.
-
Source tracking Mycobacterium ulcerans infections in the Ashanti region, Ghana.PLoS Negl Trop Dis. 2015 Jan 22;9(1):e0003437. doi: 10.1371/journal.pntd.0003437. eCollection 2015 Jan. PLoS Negl Trop Dis. 2015. PMID: 25612300 Free PMC article.
-
On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer.BMC Genomics. 2012 Jun 19;13:258. doi: 10.1186/1471-2164-13-258. BMC Genomics. 2012. PMID: 22712622 Free PMC article.
-
Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.JBI Database System Rev Implement Rep. 2017 Jan;15(1):119-139. doi: 10.11124/JBISRIR-2016-003235. JBI Database System Rev Implement Rep. 2017. PMID: 28085731
References
-
- World Health Organization . Buruli ulcer disease (Mycobacterium ulcerans infection) [Internet]. 2023. [2024 Oct 19]. https://www.who.int/news-room/fact-sheets/detail/buruli-ulcer-(mycobacte...).
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials